APRE Aprea Therapeutics Inc

Price (delayed)

$0.671

Market cap

$8.45M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.04

Enterprise value

-$32.83M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 10
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 30

Aprea Therapeutics, Inc. is a clinical stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small molecule ...

Highlights
The quick ratio has soared by 155% YoY and by 52% from the previous quarter
APRE's EPS has surged by 55% year-on-year and by 31% since the previous quarter
The equity has soared by 187% YoY but it has contracted by 7% from the previous quarter
Aprea Therapeutics's net income has increased by 11% YoY but it has decreased by 2.9% QoQ
The company's gross profit has shrunk by 99% YoY and by 96% QoQ
Aprea Therapeutics's revenue has plunged by 99% YoY and by 96% from the previous quarter

Key stats

What are the main financial stats of APRE

APRE stock price

How has the Aprea Therapeutics stock price performed over time
Intraday
-1.76%
1 week
6.09%
1 month
-7.06%
1 year
-60.76%
YTD
-21.34%
QTD
-16.37%

Financial performance

How have Aprea Therapeutics's revenue and profit performed over time
Revenue
$5,185
Gross profit
$5,185
Operating income
-$13.22M
Net income
-$12.31M
Gross margin
100%
Net margin
-237,362.8%
The company's gross profit has shrunk by 99% YoY and by 96% QoQ
Aprea Therapeutics's revenue has plunged by 99% YoY and by 96% from the previous quarter
Aprea Therapeutics's operating income has increased by 11% YoY but it has decreased by 5% from the previous quarter
Aprea Therapeutics's net income has increased by 11% YoY but it has decreased by 2.9% QoQ

Price vs fundamentals

How does APRE's price correlate with its fundamentals

Growth

What is Aprea Therapeutics's growth rate over time

Valuation

What is Aprea Therapeutics stock price valuation
P/E
N/A
P/B
0.22
P/S
6,921.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-6,331.03
APRE's EPS has surged by 55% year-on-year and by 31% since the previous quarter
The equity has soared by 187% YoY but it has contracted by 7% from the previous quarter
APRE's P/B is 73% below its 5-year quarterly average of 0.8 and 45% below its last 4 quarters average of 0.4
Aprea Therapeutics's revenue has plunged by 99% YoY and by 96% from the previous quarter

Efficiency

How efficient is Aprea Therapeutics business performance
The company's return on equity rose by 40% YoY and by 22% QoQ
Aprea Therapeutics's ROA has increased by 35% YoY and by 18% from the previous quarter

Dividends

What is APRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APRE.

Financial health

How did Aprea Therapeutics financials performed over time
The quick ratio has soared by 155% YoY and by 52% from the previous quarter
The current ratio has soared by 154% YoY and by 52% from the previous quarter
The debt is 100% smaller than the equity
The equity has soared by 187% YoY but it has contracted by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.